Previous studies had also confirmed that Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A, had efficacy in improving pathological complete response (pCR) rates when added into the neoadjuvant chemotherapy for TNBCs, with increased risk of neutropenia (39). This evidence concerns the gene VEGFA and Decreased total neutrophil count.